| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1056/NEJMCIBR022629 |
| P698 | PubMed publication ID | 12477950 |
| P2093 | author name string | Juan Amaral | |
| S Patricia Becerra | |||
| P433 | issue | 24 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | erythropoietin | Q218706 |
| P304 | page(s) | 1968-1970 | |
| P577 | publication date | 2002-12-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Erythropoietin--an endogenous retinal survival factor | |
| P478 | volume | 347 |
| Q33864879 | Aqueous humor erythropoietin levels in open-angle glaucoma patients with and without TTR V30M familial amyloid polyneuropathy |
| Q41362029 | Biologically active recombinant human erythropoietin expressed in hairy root cultures and regenerated plantlets of Nicotiana tabacum L. |
| Q38542115 | Diabetic Retinopathy: Vascular and Inflammatory Disease. |
| Q84482290 | Diabetic retinopathy |
| Q37733102 | Dietary hyperglycemia, glycemic index and metabolic retinal diseases |
| Q54572418 | Effects of single intravitreal rhEPO injection on light-induced retinal injury in rats. |
| Q46689938 | Elevated erythropoietin mRNA and protein concentrations in the developing human eye. |
| Q43230857 | Enalapril alters expression of key growth factors in experimental diabetic retinopathy |
| Q47806649 | Erythropoietin in diabetic retinopathy. |
| Q26744850 | Erythropoietin in ophthalmology: A literature review |
| Q37968179 | Erythropoietin produced by the retina: its role in physiology and diabetic retinopathy |
| Q38928508 | Growth Factors in the Pathogenesis of Retinal Neurodegeneration in Diabetes Mellitus |
| Q37667292 | Hypoxia-Inducible Factor-1α Target Genes Contribute to Retinal Neuroprotection |
| Q46799587 | Intravitreal administration of erythropoietin and preservation of retinal ganglion cells in an experimental rat model of glaucoma |
| Q42787068 | Landmark advances in the development of erythropoietin |
| Q37678807 | Mediators of ocular angiogenesis |
| Q37301624 | Mouse genetic models: an ideal system for understanding glaucomatous neurodegeneration and neuroprotection |
| Q42957709 | Neurodegeneration in diabetic retina and its potential drug targets |
| Q33887925 | Neurodegeneration: An early event of diabetic retinopathy |
| Q38009713 | Neuroprotection in diabetic retinopathy |
| Q37412643 | Neuroprotective effects of erythropoietin against oxidant injury following brain irradiation: an experimental study |
| Q46292739 | Pharmacokinetic and toxicity study of intravitreal erythropoietin in rabbits |
| Q33702107 | Serum erythropoietin levels in patients with central serous chorioretinopathy |
| Q33379554 | Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy |
| Q45127739 | Systemic but not intraocular Epo gene transfer protects the retina from light-and genetic-induced degeneration |
| Q59800987 | The Role of Endogenous Neuroprotective Mechanisms in the Prevention of Retinal Ganglion Cells Degeneration |
| Q34100527 | The retinal pigment epithelium: something more than a constituent of the blood-retinal barrier--implications for the pathogenesis of diabetic retinopathy. |
| Q28576585 | Up-regulated endogenous erythropoietin/erythropoietin receptor system and exogenous erythropoietin rescue retinal ganglion cells after chronic ocular hypertension |
| Q73487270 | Vision impairment therapies |
| Q27028225 | Vitreous mediators in retinal hypoxic diseases |
Search more.